Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 7/20 | 0.33 |
| ▸ | PIM1 | P11309 | 3/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662814 | 0.83 | CREBBP (0.44) | CREBBPHTR3AMAP3K12PIM1PIM3 | |
| SCHEMBL23762061 | 0.81 | HTR3A (0.45) | CREBBPHTR3AMAPT | |
| SCHEMBL21237335 | 0.80 | CREBBP (0.40) | CREBBPHTR3AMAP3K12PIM1PIM3 | |
| SCHEMBL23761963 | 0.77 | HTR3A (0.64) | HTR3A | |
| SCHEMBL19662986 | 0.71 | CREBBP (0.52) | CREBBP | |
| SCHEMBL18848482 | 0.69 | NOS1 (0.38) | — | |
| SCHEMBL19662787 | 0.69 | CREBBP (0.47) | CREBBPHTR3APIM1PIM3PIM2 | |
| SCHEMBL29909738 | 0.66 | PDPK1 (0.53) | MAPT | |
| SCHEMBL21237241 | 0.66 | CREBBP (0.43) | CREBBPHTR3APIM1PIM3PIM2 | |
| SCHEMBL21237648 | 0.64 | CREBBP (0.46) | CREBBPHTR3ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |